Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

目录号：S1098 别名： PF-01367338 中文名称：瑞卡帕布磷酸盐

Rucaparib (AG-014699) phosphate Chemical Structure

CAS No. 459868-92-9

Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂，无细胞试验中作用于PARP1的Ki为1.4 nM，对其余8个PARP位点也有结合亲和力。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1091.92 现货
RMB 980.68 现货
RMB 1730.04 现货
RMB 5483.69 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Rucaparib (AG-014699) phosphate发表文献97篇：

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂，无细胞试验中作用于PARP1的Ki为1.4 nM，对其余8个PARP位点也有结合亲和力。Phase 3。
特性 AG-014699是第一个用于人类癌症疗法的PARP 抑制剂。
靶点
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外研究

AG-014699有效抑制纯化的全长人类PARP-1，作用于LoVo和SW620细胞显示出强PARP抑制效果。AG-014699是AG14447的磷酸盐形式，且是第一个和temozolomide联用用于临床实验的PARP抑制剂。[1] AG-014699的辐射增敏性是由于下游NF-κB激活的抑制，及SSB修复抑制。AG-014699可以作用于DNA损伤激活的NF-κB，且克服传统NF-κB抑制剂的毒性，不会损害其他重要的炎症反应。[2]1μM AG-014699作用于D283Med细胞时抑制PARP-1活性达97.1%。[3]在NB-1691, SH-SY-5Y, 和SKNBE(2c)细胞中AG-014699明显增强Topotecan和Temozolomide的细胞毒性。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M2fITmZ2dmO2aX;uJGF{e2G7 MUSwMlEwOS93MECvNVAxOCCwTR?= MkC1bY5pcWKrdIOgVGFTWCCjY4Tpeol1gSCjdDDzeIFzfGmwZzDjc45k\XKwdILheIlwdiCxZjC1NFAhdk1? M2H2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
BT474 NFzXVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULSZ|h[PTByIH7N NHTUXFIyOOLCk{G1xsBl NFzjV2lz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
SKBR3 NEHlOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHqNpNNPTByIH7N NYmyOXVFOTEkgKOxOeKh\A>? NF;aV2Zz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 NVvzNodERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
AU565 M3\acmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj5RWZtPTByIH7N NFf2V|gyOOLCk{G1xsBl M3HnWJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
EFM192A M32yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG1NFAhdk1? M2TXbFEx6oDVMUZCpIQ> NUHJSIViemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M4GwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
MDA-MB-231 NIjQS3VHfW6ldHnvckBCe3OjeR?= M4W3SlExNzJyL{SwJO69VQ>? MXGyOEBp NWLLXnRrcW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 NIfmN5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGXJWm0xNjFvNECg{txO MoXUNlQhcA>? NVzSXG52UUN3MPMAjV3jiIlzNz63O:Kh|ryP MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231 MVzBdI9xfG:|aYOgRZN{[Xl? M1XpdVExNzJyL{SwJO69VQ>? MYCyOEBp NXTGc2JjcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MkDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
MDA-MB-231 NG\1Z25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr2NVAwOjBxNECg{txO NViwZVdMOjRiaB?= Ml3lZoxw[2u|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hcW5iR{KvUUBxcGG|ZR?= NVz0U4VXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
H460 NF3tXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7COHU1ODBibl2= MofnNlTDqGh? MoLBbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= NVTGWYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVE3OTFpPkK0OFEyPjFzPD;hQi=>
A549  M4HWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH5OFAxKG6P MY[yOOKhcA>? MnvabY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= NHvlc3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVYyOSd-MkS0NVE3OTF:L3G+
DT40 NUftRoU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSfXlxUUN3ME2yNUBvVQ>? M3v2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W2PFE{Lz5{NEO1OlgyOzxxYU6=
DU145 NYfEbG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor4TWM2OD1zODDuUS=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR|NU[4NVM9N2F-
COLO704 NIq0dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTiSXZKSzVyPUKuOVIhyrFiMD62O{DPxE1? Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVMANAb MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPwTWM2OD1{LkW4JOKyKDBwM{ig{txO NV\xWWFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV177 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDV3p1UUN3ME2yMlc5KMLzIECuO|Eh|ryP NYjYXJhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OAW28 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ofGlEPTB;Mz62NUDDuSByLkK4JO69VQ>? NUOzNVVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVSAHO M2nsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwNkSgxtEhOC5|MzFOwG0> Mn\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVKATE MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\XdmlEPTB;Mz62OEDDuSBzLke5JO69VQ>? NYO5eGVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVCAR3 NYDtW4hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D5[WlEPTB;Mz63OEDDuSByLkSwJO69VQ>? NWnTSlVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
PEO14 NFHNNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HWWGlEPTB;Mz64OEDDuSByLke2JO69VQ>? M4L0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
A2780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1|Lkm0JOKyKDBwMkWg{txO NGrENW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVTOKO M{\j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PkN2lEPTB;ND6xOEDDuSBzLkWzJO69VQ>? NH\3c4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KURAMOCHIb MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwM{SgxtEhOC5{OTFOwG0> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
TOV21G MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD13LkC3JOKyKDFwM{Cg{txO NGPyWZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVISE NXjCUlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTVwNkigxtEhOC5{MzFOwG0> NV7YUGZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
KK MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHeyOGlKSzVyPU[uNVUhyrFiMT60NkDPxE1? NHv1UZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
RMUGS MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwVGU1UUN3ME23MlA{KMLzIEGuPFMh|ryP NH3zZ4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEO6 NXP5TJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;QTWM2OD15LkC2JOKyKDBwN{Sg{txO NH:4R2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA429 NHO0SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;rS2lEPTB;OD6yPUDDuSBzLk[0JO69VQ>? Mn;ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV167 M1r4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPSTWM2OD16LkOzJOKyKDFwMUig{txO NYfxe2hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
RMG1 M1;LU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO2bmlPUUN3ME25MlMzKMLzIEKuN|Yh|ryP M3HVcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR5 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLFdW1IUUN3ME25MlUxKMLzIEKuOVkh|ryP MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO21 NWPxWmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi3TlhKSzVyPUmuPVIhyrFiMT64O{DPxE1? MnnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
ES2 NH\5NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTVTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? NHHaNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
Tyk-nu NGPRcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHUTWM2OD1zMD6yNEDDuSBzLkGyJO69VQ>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
CAOV3 NHfUdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFyLkO3JOKyKDBwOEeg{txO Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV207 M4rZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDWTWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? NXe3R|ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
HEY M3LLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7wXJY1UUN3ME2xN{4xOSEEsTCwMlc2KM7:TR?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
DOV13 NX;SemMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzb4xVUUN3ME6xOUDPxE1? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO27 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DlcmlEPTB-MUWg{txO M3vRR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
HEY C2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT6TWM2OD5zNTFOwG0> NVzLSXZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
KOC-7cc NEK4UG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKzU2xKSzVyPkG1JO69VQ>? NFfmSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
MCASb NUT4NZNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3BTWM2OD5zNTFOwG0> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OAW42 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\xfJhWUUN3ME6xOUDPxE1? NHjhd|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV2008 NHLMb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2bFRIUUN3ME6xOUDPxE1? MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV90 NVvS[G9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;xNWlEPTB-MUWg{txO NYDpNVNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVCA420b NHjoV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjQTW1KSzVyPkG1JO69VQ>? NWPFXIVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVCA432 M3ftZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jEV2lEPTB-MUWg{txO NUTQSlQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
PEA2 M1;JXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm0TWM2OD5zNTFOwG0> NHvzSZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
SKOV3 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRjF3IN88US=> MlzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
TOV112D NGO3V|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPZNGU4OC1|IN88US=> NWH6TFI2UUN3ME6xOUDPxE1? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
C4-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUewMVMh|ryP NEDQXVEyPCCm NU\ISG9yTE2VTx?= NWDKRYJS\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NVfnS5pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
PC3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnHNE0{KM7:TR?= MWOxOEBl NEHyb5hFVVOR MY\k[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NEHFfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
DU145 NVzvZ3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yweVAuOyEQvF2= NHG1dHEyPCCm M{TaXWROW09? NV\EWY5u\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
VCaP  NWXpOJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDYZlExNTNizszN NWjJdGNiOTRiZB?= NY\xdotJTE2VTx?= MWPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NXrEfmJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
LNCaP  M3;5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfUNE0{KM7:TR?= M{fqXlE1KGR? NVXQfWFWTE2VTx?= NGrCNWNl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 NUnGOHVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
MDA-MB-468 MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1\wemlEPTB;OT63JO69VQ>? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ5OEG2NUc,OjJ4N{ixOlE9N2F-
MDA-MB-231 M3ztV2NmdGxiVnnhZoltcXS7IFHzd4F6 NXfyNpJOUUN3ME2xN{DPxE1? Mnv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4N{ixOlEoRjJ{Nke4NVYyRC:jPh?=
Cal-51 MofIR4VtdCCYaXHibYxqfHliQYPzZZk> NXLYc4VkUUN3ME24MlYh|ryP NVviPVI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O|gyPjFpPkKyOlc5OTZzPD;hQi=>
LoVo MkLOSpVv[3Srb36gZZN{[Xl? NEDIdow{OCCvaX7z Ml3PTY5pcWKrdHnvckBw\iCSQWLQJIlvKGi3bXHuJGxwXm9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7KFHEVEkuemmkb4PlJJBwdHmvZYLpfoF1cW:wIH\vdkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwMEC0Olkh|ryPLh?= NVXLOWg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
MX1 MUHDfZRwfG:6aXPpeJkh[XO|YYm= MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBDWkODMT3k[YZq[2mnboSgbJVu[W5iTWixJINmdGy|LDDFR|UxKD1iMD6wNFU{KM7:TT6= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
Rosetta2 (DE3) NXXvVXJMTnWwY4Tpc44h[XO|YYm= NHXCUWRKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiNojobZMufGGpZ3XkJGFTXER4IDi4O|MhfG9iMUG2NUkh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliUn;z[ZR1[TJiKFTFN{kh[2WubIOgeZNqdmdiTlHEL{BieyC|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyIE2gNE4xOTRizszNMi=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe3NEc,OjR7MEC3O|A9N2F-
Rosetta2 (DE3) M3e2SmZ2dmO2aX;uJIF{e2G7 NH[3WFZKdmirYnn0bY9vKG:oIHj1cYFvKD[6aHnzMZRi\2enZDDBVnRFPSBqMUCzNEB1dyBzM{G3LUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCUb4PleJRiOiBqRFWzLUBk\WyuczD1d4lv\yCQQVSrJIF{KHO3YoP0doF1\SCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlAzPSEQvF2u M132RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
LoVo MXvDfZRwfG:6aXPpeJkh[XO|YYm= MkPLNE41KHWP M{\idFUh\GG7cx?= M2fC[nBwfGWwdHnheIlwdiCxZjD0[Y1wgm:ub33p[IUucW6mdXPl[EBkgXSxdH;4bYNqfHliaX6gbJVu[W5iTH;Wc{Bk\WyuczDhd5Nme3OnZDDhd{B1\W2xen;sc41q\GViR1m1NEBifCByLkSgeW0h[W[2ZYKgOUBl[Xm|IHL5JGNmdGy2aYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjF2NDFOwG0v NWT0TnhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
Capan1 NFexOIJEgXSxdH;4bYNqfHliYYPzZZk> MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBDWkODMj3k[YZq[2mnboSgbJVu[W5iQ3HwZY4yKGOnbHzzMEBGSzVyIE2gNE43ODlizszNMi=> NIPFSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MDA-MB-436 MYnBcpRq[2GwY3XyJIF{e2G7 NVn5[JBEQTZiaILz NUXkOnZ5SW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGJTS0FzLXTl[olkcWWwdDDNSGEuVUJvNEO2JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVAhRSB|IN88UU4> M3HVXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{SyPFY5Lz5{NkO0Nlg3QDxxYU6=
OVCAR3 MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHW2VZAzPCCqcoO= M3PTN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI{KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCzMlMyKM7:TT6= M1\jclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW2NVA3Lz5{OUS1OlExPjxxYU6=
MRC5 NUDXOm5tS3m2b4TvfIlkcXS7IHHzd4F6 M1TpOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1TSzViY3XscJMtKEWFNUCgQUA5NjV|IN88UU4> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MCF7 MWfBcpRq[2GwY3XyJIF{e2G7 Mn2xPVYhcHK| NYT5dpRjSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFE6NjR5IN88UU4> NVTwVYN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N|QzQDZ6PD;hQi=>
A673 MmXNdWhVWyCjc4PhfS=> NGOyRpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= M2raTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MYnxTHRUKGG|c3H5 NGL1NGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NFXqe5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NWPaeW9CeUiWUzDhd5NigQ>? MlvmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> NUnwRYZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MVTxTHRUKGG|c3H5 M2LrdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? M3m2U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MoThdWhVWyCjc4PhfS=> NEfYZWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ M{n6b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

24085845 27960087
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

23565244 27515310 30589644
体内研究 AG-014699无毒，明显增强D384Med移植瘤DNA修复功能蛋白中temozolomide诱导的TGD。药物动力学研究显示在脑组织中也检测到AG-014699，说明AG-014699用于治疗颅内恶性肿瘤具有潜在可能。[3]活体模型(NB1691和SHSY5Y移植瘤)研究显示AG-014699增强temozolomide的抗癌活性，产生彻底且持久的肿瘤衰退现象。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[3]
- 合并

激酶实验:

不同浓度(0到1μ)AG-014699作用于5×103D283Med 细胞，与只用DMSO处理5×103D283Med细胞相比，来测定PARP活性抑制率。参考GCLP验证试验的PAR标准曲线，在和NAD+及寡核苷酸(底物和激活剂)温育的6分钟期间，使用10H PAR抗体，通过PAR形成量的免疫检测，在细胞样本中测量最大程度刺激的PARP活性。
细胞实验： [3]
- 合并
  • Cell lines: D425Med, D283Med和D384Med细胞
  • Concentrations: 0.4 μM
  • Incubation Time: 3或5天
  • Method: 髓母细胞瘤细胞系包含D425Med, D283Med，和D384Med细胞，分别按1×103, 3×103，和3×103密度接种在96孔板上。接种24小时(D384Med细胞)或48小时(D283Med和D425Med细胞)后，细胞用不同浓度temozolomide处理。培养3天(D425Med和D384Med细胞)或5天(D283Med细胞)后，通过XTT细胞增殖检测试剂盒检测细胞活力。用DMSO处理的对照组和0.4μ AG-014699处理的实验组的百分比表示细胞生长。计算temozolomide单独使用或者和AG-014699联用时的GI50值。Temozolomide单独使用时的GI50值和与AG-014699联用时的GI50值之比就是趋化因子50（PF50）值。
    (Only for Reference)
动物实验：[3]
- 合并
  • Animal Models: 携带D283Med移植瘤的CD-1裸鼠
  • Dosages: 1 mg/kg
  • Administration: 腹腔注射，每天1次或4次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.36
化学式

C19H18FN3O.H3PO4
CAS号 459868-92-9
储存条件 粉状
溶于溶剂
别名 PF-01367338

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03954366 Active not recruiting Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives Neoplasms Clovis Oncology Inc. May 8 2019 Phase 1
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine May 15 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

  • G007-LK New

    G007-LK是一种有效的选择性tankyrase抑制剂，对TNKS1/2的IC50分别为46 nM 和 25 nM。

  • NU1025 New

    NU1025 (NSC 696807)是一种有效的 PARP 抑制剂，IC50 为 400 nM。

  • Blasticidin S HCl New

    Blasticidin S HCl是一种从Stretomyces girseochromogenes中分离得到的核苷antibiotic，也是DNA和蛋白质合成的抑制剂，用于筛选携带brs或BSD抗性基因的转染细胞。

  • Olaparib (AZD2281)

    Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂，IC50为5 nM/1 nM，其对PARP1/2的作用比对Tankyrase-1效果高300倍。在BRCA突变的细胞中，Olaparib可以显著地诱导线粒体自噬相关的细胞自噬。

    Features:Olaparib是第一批PARP抑制剂之一。

  • Veliparib (ABT-888)

    Veliparib (ABT-888, NSC 737664)是一种有效的PARP1和PARP2抑制剂，无细胞试验中Ki分别为5.2 nM和2.9 nM，对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。

    Features:ABT-888增强常见癌症疗法的效果，比如放射疗法和烷基化剂。

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673, LT-673)是一种新型的PARP抑制剂，无细胞试验中对PARP1的IC50为0.57 nM。它也是有效的PARP-2抑制剂，但不抑制PARG，对PTEN突变型高度敏感。Phase 3。

    Features:到目前为止报道的最有效的选择性PARP抑制剂。

  • Iniparib (BSI-201)

    Iniparib (BSI-201, NSC-746045, IND-71677)是一种PARP1抑制剂，在三阴性乳腺癌(TNBC)中具有作用效果。Phase 3。

  • AG-14361

    AG14361是一种有效的PARP1抑制剂，无细胞试验中Ki为<5 nM。它比benzamides至少有效1000倍。

    Features:AG14361是第一个高效的PARP-1抑制剂，具有选择性和体内活性，增强化疗和放射治疗人类癌症。

Tags: 购买Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate供应商 | 采购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate价格 | Rucaparib (AG-014699) phosphate生产 | 订购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID